A Phase 1 open-label clinical trial has explored the intranasal application of botulinum toxin type A (“Haytox”) in patients with allergic and nonallergic rhinitis. Fourteen participants received 40 units of botulinum toxin type A via a mucosal atomization device, with no serious adverse events reported. The study demonstrated a statistically and clinically significant reduction in Total Nasal Symptom Score (TNSS) and a significant drop in Visual Analog Scale (VAS) scores up to Week 12.
Although the findings are preliminary, the absence of adverse events supports the safety of intranasal botulinum toxin and encourages further controlled trials to define dosing, duration, and comparative efficacy against standard therapies. To read more, click here If intranasal botulinum toxin proves safe and effective, could it redefine how we manage chronic rhinitis resistant to medical therapy?
